Cargando…
Cutaneous cryptococcosis in a patient with myelofibrosis receiving JAK‐inhibitor
Autores principales: | Chen, Jui‐Che, Yuan, Chang‐Tsu, Lin, Chien‐Chin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175765/ https://www.ncbi.nlm.nih.gov/pubmed/35846204 http://dx.doi.org/10.1002/jha2.339 |
Ejemplares similares
-
Development of JAK2 positive myelofibrosis on a background of chronic myeloid leukaemia
por: Mullen, Christopher Gerard, et al.
Publicado: (2022) -
Acute myelofibrosis superseding B‐lymphoblastic leukemia/lymphoma
por: El Hussein, Siba, et al.
Publicado: (2023) -
Pleomorphic circulating megakaryocytes in a case of CALR positive primary myelofibrosis in leukemic transformation
por: Moshref Razavi, Habib
Publicado: (2021) -
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts
por: Harrison, Claire N., et al.
Publicado: (2022) -
Primary cutaneous T‐follicular helper lymphoma
por: Fenu, Elena M., et al.
Publicado: (2023)